IKT

2.23

5.69% 0.12

Vorhandelsmarkt: 2.13 -0.10 -4.48%

Inhibikase Therapeutics Inc (IKT)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$2.11

Offen:

$2.11

24-Stunden-Volumen:

1.07M

Relative Volume:

1.20

Marktkapitalisierung:

$350.18M

Einnahmen:

$79,600

Nettoeinkommen (Verlust:

$-48.26M

KGV:

-4.5307

EPS:

-0.4922

Netto-Cashflow:

$-28.24M

1W Leistung:

+13.78%

1M Leistung:

+21.86%

6M Leistung:

+35.15%

1J Leistung:

+21.20%

1-Tages-Spanne:

$2.10

$2.26

1-Wochen-Bereich:

$1.93

$2.36

52-Wochen-Spanne:

$1.33

$2.36

Inhibikase Therapeutics Inc Stock (IKT) Company Profile

Firmenname

Inhibikase Therapeutics Inc

Sektor

Healthcare (1089)

Branche

Biotechnology (603)

Telefon

(302) 295-3800

Adresse

1000 N. WEST STREET, SUITE 1200, WILMINGTON

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-08-13

Neueste SEC-Einreichungen

IKT's Discussions on Twitter

Compare IKT vs VRTX, REGN, ARGX, RVMD, ALNY

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IKT Inhibikase Therapeutics Inc	2.23	350.18M	79,600	-48.26M	-28.24M	-0.4922
VRTX Vertex Pharmaceuticals Inc	480.50	121.95B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	672.15	70.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	846.19	52.94B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	180.39	38.35B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	272.67	36.40B	4.29B	577.22M	641.34M	4.2086

Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-04	Eingeleitet	Ladenburg Thalmann	Buy
2026-01-21	Eingeleitet	BofA Securities	Buy
2025-12-26	Eingeleitet	H.C. Wainwright	Buy
2025-12-11	Eingeleitet	Cantor Fitzgerald	Overweight
2025-02-12	Herabstufung	H.C. Wainwright	Buy → Neutral

Inhibikase Therapeutics Inc Aktie (IKT) Neueste Nachrichten

Jul 20, 2026

Inhibikase Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition - Moomoo

Jul 20, 2026

Frontier tech research, news & data - MLQ.ai

Jul 20, 2026

Jul 18, 2026

RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics - Bitget

Jul 18, 2026

Inhibikase Therapeutics (NASDAQ:IKT) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat

Jul 18, 2026

Jul 17, 2026

RA Capital discloses 25M-share stake in Inhibikase Therapeutics (IKT) - Stock Titan

Jul 17, 2026

RA Capital (NASDAQ: IKT) reports 25M-share, 15.9% stake in Inhibikase - Stock Titan

Jul 17, 2026

Jul 16, 2026

IKT Receives FDA Orphan Designation for Pulmonary Arterial Hyper - GuruFocus

Jul 16, 2026

Jul 15, 2026

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility - Sahm

Jul 15, 2026

Inhibikase raises $50M to fund PAH program - TipRanks

Jul 15, 2026

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Rating of "Buy" by Brokerages - MarketBeat

Jul 15, 2026

Jul 14, 2026

Inhibikase Therapeutics Shares Rise on $50M At‐the‐Market Share Sale - Moomoo

Jul 14, 2026

Inhibikase raises $50 million through stock sale to RA Capital - Investing.com

Jul 14, 2026

Inhibikase Therapeutics Sells $50M of Stock to RA Capital via ATM Facility - TradingView

Jul 14, 2026

Inhibikase Therapeutics (NASDAQ:IKT) Rating Increased to Strong-Buy at LADENBURG THALM/SH SH - MarketBeat

Jul 14, 2026

Inhibikase raises $50 million through stock sale to RA Capital By Investing.com - Investing.com Canada

Jul 14, 2026

Inhibikase Therapeutics (Nasdaq: IKT) sells 25M shares for $50M cash - Stock Titan

Jul 14, 2026

Inhibikase's $50M share sale could support Phase 3 PAH readout - Stock Titan

Jul 14, 2026

Inhibikase Therapeutics (NASDAQ:IKT) Shares Down 3.9%Here's What Happened - MarketBeat

Jul 14, 2026

Jul 10, 2026

Inhibikase Therapeutics Q1 2026 Earnings: EPS Beat Fails to Lift Stock as Cash Burn ContinuesAnnual Earnings Summary - dars.gov.et

Jul 10, 2026

Jul 07, 2026